Saturday, May 24, 2025

Generix Named in the 2025 Gartner® Magic Quadrant™ for Warehouse Management Systems (WMS) for the Seventh Consecutive Year

 (BUSINESS WIRE)--Generix, a global business software company offering an expansive portfolio of SaaS solutions for supply chain, finance, commerce, and B2B integration, today announces it has been recognized by Gartner in the 2025 Gartner® Magic Quadrant™ for Warehouse Management Systems (WMS).


This is the seventh consecutive year that Generix has been recognized for its portfolio of WMS Solutions. Designed to scale as supply chain operations grow from simple to complex flows, Generix WMS and Solochain WMS are currently in more than 2,000 warehouses globally.


“We are honored to be recognized in the Gartner® Magic Quadrant™ WMS for the seventh consecutive year. Generix continues its commitment to providing WMS for every warehousing need at a global scale. With our two recognized WMS solutions, Generix WMS and Solochain WMS, we continue to innovate to better serve customer needs with the introduction of industry game-changing AI use-cases such as resource planning and computer vision,” said Si-Mohamed Saïd, Chief Marketing & Product Officer, Generix.


Generix offers a comprehensive portfolio of supply chain solutions, encompassing transportation and yard management, logistics and order replenishment management, as well as electronic data interchange (EDI). The Generix product suite also includes a Transportation Management System (TMS), omnichannel order management, and in-store inventory management-enhanced further by the acquisitions of DDS and Keyneo.


Generix WMS is a global, customizable warehouse management system with in-depth functionality and unlimited scale. Generix Solochain is a fast-start warehouse management system with proven, out-of-the-box functionality and the flexibility to quickly adapt.


Earlier this year, Generix launched Solochain Now, a WMS packaged solution bringing together the core capabilities of Solochain WMS services and industry best-practices and enabling companies to be up-and-running in as little as 16 weeks. The packaged solution offers best-in-class functionality quickly, integrating standard business processes and industry best practices. The pre-integrated configuration quickly adapts to new priorities without overloading IT resources.


Gartner Disclaimer:


Gartner, Magic Quadrant for Warehouse Management Systems, 01 May 2025, Simon Tunstall, Dwight Klappich, Rishabh Narang, Federica Stufano


GARTNER is a registered trademark and service mark, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.


“Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.”


About Generix


Generix is a global SaaS company helping connect businesses together to turn each digital connection into digital value. It offers a leading portfolio of cloud solutions and services powered by AI to drive with confidence the most mission-critical digital business processes in supply chain, finance and commerce. It also provides end-to-end B2B integration and collaboration solutions so companies can fully operate across digital business networks. Nearly 900 Generix talents are dedicated to best serve over 5,000 customers across more than 60 countries. The company helps to process more than 17 billion messages, prepare more 600 million pallets, manage over 500 million invoices and more than 1 million transport operations per year. Generix believes in the immense growth potential of the networked economy in a sustainable world. More info: www.generixgroup.com


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250523292647/en/



Permalink

https://www.aetoswire.com/en/news/54259295


Contacts

 

Media Inquiries:

Laurel Case

news@talesplash.com

+1 315-663-6780


 

Friday, May 23, 2025

Kioxia Holdings Corporation Wins IPO of the Year Award in the Equity Category at the DealWatch Awards 2024

 (BUSINESS WIRE)--Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced that it had won the IPO of the Year award in the Equity category at the DealWatch Awards 2024, organized by DealWatch, the most authoritative source of real-time intelligence for deal activity within Japan's capital markets. The award was presented at a ceremony held on May 20.


The DealWatch Awards recognize outstanding issuers of bonds or equities in the Japanese capital market, as well as Japanese issuers who have conducted offerings overseas, and the securities firms that manage these transactions. The awards for 2024 comprised six categories: Overall, Bonds, Local Government Bonds, Cross-Border Bonds, Sustainable Finance, and Equity. Selection is based on criteria such as the appropriateness of pricing in the issuance market, price formation after transition to the trading market, contribution to the development of capital markets, and innovative efforts, with the awards designed to promote Japan's markets to a global audience.


DealWatch commented positively on our listing on the Tokyo Stock Exchange Prime Market on December 18, 2024, stating it was "an unprecedented large-scale IPO adopting Japan's first pre-approval notification (S-1) procedure.” They added, “Active discussions were conducted with institutional investors regarding appropriate pricing, effectively promoting the growth potential of the NAND market and the company's competitive edge, thereby stimulating demand from individual investors and institutional investors both domestically and internationally. This resulted in extremely strong after-market performance."


Moving forward, the Kioxia Group remains committed to fulfilling its corporate social responsibilities and striving for sustainable growth and enhanced corporate value to meet the expectations of its stakeholders.


About Kioxia


Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with “memory” by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, automotive systems, data centers and generative AI systems.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250523319080/en/



Permalink

https://www.aetoswire.com/en/news/2305202546914


Contacts

Kota Yamaji

Public Relations

Kioxia Holdings Corporation

+81-3-6478-2319

kioxia-hd-pr@kioxia.com

Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025

 

  • Data from Phase 3 MANEUVER study demonstrating significant improvements in physical function and symptoms in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, to be featured in oral presentation
  • Latest results for potential first-in-class anti-CEACAM5 ADC precemtabart tocentecan (M9140) highlight strong rationale for further development in colorectal cancer (CRC)

Not intended for Canada-, UK- or US-based media

 

(BUSINESS WIRE) -- Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago. The presentations include the Phase 3 MANEUVER data for potentially best-in-class pimicotinib in the treatment of the rare tumor TGCT, as well as data from both company- and investigator-sponsored studies highlighting the company’s focus on advancing differentiated molecules to tackle some of the most challenging cancers.

“The new clinical data we are presenting at ASCO showcase our dedication to advancing innovative therapies for a wide range of diseases—spanning from common cancers to rare non-malignant neoplasms,” said Victoria Zazulina, M.D., Head of Development Unit, Oncology, for the Healthcare business of Merck. “From encouraging early data for our lead antibody-drug conjugate, precemtabart tocentecan, in patients with advanced CRC, to new Phase 2 findings and real-world evidence that reinforce the value of BAVENCIO first-line maintenance as a treatment option for advanced bladder cancer, to detailed Phase 3 results for pimicotinib in tenosynovial giant cell tumor, we are working to advance treatments that provide hope to patients and their families.”

Highlights of the company’s data include:

First presentation of Phase 3 MANEUVER data for pimicotinib in the treatment of TGCT (Abstract 11500)

Detailed results from Part 1 of the Phase 3 MANEUVER study of pimicotinib in the treatment of patients with TGCT, conducted by Abbisko Therapeutics Co., Ltd., will be presented for the first time during the Sarcoma Oral Abstract Session on June 1, at 9:57 a.m. CDT. In the trial, pimicotinib significantly improved objective response rate versus placebo, the primary endpoint, as well as all key secondary endpoints, and was well-tolerated. Pimicotinib is being developed by Abbisko Therapeutics; Merck holds the rights to commercialize pimicotinib worldwide.

Latest data for potentially first-in-class precemtabart tocentecan (Abstracts 3038 & TPS3165)

The company continues to progress the clinical investigation of its lead antibody-drug conjugate (ADC), precemtabart tocentecan. New findings from the Phase 1 PROCEADE-CRC 01 study include data from the dose-optimization part in 60 irinotecan-refractory metastatic CRC patients (3L+) demonstrating encouraging efficacy at doses of 2.4mg/kg and 2.8mg/kg every 3 weeks (Q3W) and a predictable and manageable safety profile. These data, which showed a higher ORR and similar safety at the 2.8 mg/kg dose, support the rationale for selecting this as the recommended dose for further development in CRC and other solid tumors, including those cancer types being investigated in the ongoing Phase 1b/2 PROCEADE-PanTumor study (NCT06710132). More mature data for PROCEADE-CRC-01 and details on the design for the PROCEADE-PanTumor study investigating precemtabart tocentecan in patients with locally advanced/metastatic non-small cell lung, gastric, gastroesophageal junction or pancreatic cancer will be presented at the congress.

New findings further building on the benefit from BAVENCIO® (avelumab) in the first-line maintenance setting in advanced bladder cancer (Abstracts 4501, e16561, e23275, 9543)

Interim results from the Phase 2 JAVELIN Bladder Medley trial will be presented, focusing on the efficacy of BAVENCIO in combination with the anti-Trop-2 ADC sacituzumab govitecan (Trodelvy®, Gilead Sciences) for patients with advanced urothelial carcinoma (UC) who are progression-free after first-line platinum-containing chemotherapy. When used in the maintenance setting, the combination therapy significantly improved progression-free survival (PFS) versus BAVENCIO alone (HR 0.49 [95% CI, 0.31-0.76]); median PFS was 11.17 months versus 3.75 months, respectively. Overall survival (OS) data were immature at the time of analysis. Treatment-related adverse events were more frequent in the combination group (97.3%) compared with BAVENCIO monotherapy (63.9%).

The company also will present real-world evidence that reinforces the clinical trial findings from the Phase 3 JAVELIN Bladder 100 study of BAVENCIO as a first-line maintenance therapy in patients with locally advanced/metastatic UC. The data highlight the effectiveness and safety of BAVENCIO in routine clinical practice and heterogenous populations as well as the importance of personalized treatment decision-making.

New research reinforcing the role of ERBITUX® (cetuximab) in colorectal cancer (Abstracts 3513, LBA3500)

Investigator-sponsored research continues to reinforce ERBITUX as the backbone of treatment in CRC, including a rapid oral presentation on the final analysis of the FIRE-4 study evaluating the efficacy of cetuximab re-challenge in patients with RASwt mCRC. The study demonstrated greater overall response rate (ORR) in the ERBITUX-containing experimental arm versus physicians’ choice of treatment (11.9% vs 28.9%) and numerically higher OS and PFS. Additional data from Pfizer’s Phase 3 BREAKWATER trial, evaluating the clinical efficacy of the combination of mFOLFOX6, encorafenib and ERBITUX in metastatic BRAF V600E-mutant CRC, will be featured in the Cancers of the Colon, Rectum, and Anus session. Merck holds the marketing rights to Erbitux globally, outside of the US and Canada.

Select Merck-related abstracts accepted for the ASCO 2025 Annual Meeting include (all times in CDT):

Title

Lead Author

Abstract

Session Information

Pimicotinib

 

 

 

Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of Phase 3 MANEUVER study

Niu X

11500

Session Title: Sarcoma

Date: Sunday, June 1, 2025

Session Time: 9:45 AM – 12:45 PM

Presentation Time: 9:45 AM – 9:57 AM

Location: S100a

Precemtabart tocentecan (M9140)

 

 

 

Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer (mCRC): Results from the dose optimization of the phase 1 PROCEADE CRC-01 study

Kopetz S

3038

Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Date: Monday, June 2, 2025

Session Time: 1:30 PM – 4:30 PM

Location: Hall A

BAVENCIO® (avelumab)

Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): Interim analysis from the JAVELIN Bladder Medley phase 2 trial

Hoffman-Censit J

4501

Session Title: Genitourinary Cancer—Kidney and Bladder

Date: Sunday, June 1, 2025

Session Time: 9:45 AM – 12:45 PM

Presentation Time: 9:57 AM – 10:09 AM

Location: Hall D2

Differences in patient (pt) characteristics and therapy choice across treatment (tx) groups in locally advanced or metastatic urothelial cancer (la/mUC) in the US: A survey on unmet patient needs

Milloy N

e16561

Session Title: Publication Only: Genitourinary Cancer—Kidney and Bladder

 

Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting

Nizam A

e23275

Session Title: Publication Only: Quality Care/Health Services Research

Real-world safety and effectiveness of avelumab in immune-compromised (IC) and non-IC patients with Merkel cell carcinoma (MCC): Results from a prospective German registry (MCC-TRIM)

 

Becker J

9543

 

Session Title: Publication Only: Genitourinary Cancer—Kidney and Bladder

ERBITUX® (cetuximab)

 

 

 

FIRE-4 (AIO KRK-0114): Randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab

Weiss L

3513

Session Title: Gastrointestinal Cancer—Colorectal and Anal

Date: Sunday, June 1, 2025

Session Time: 11:30 AM – 1:00 PM

Presentation Time: 11:36 AM – 11:42 AM

Location: Hall D1

First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses

Elez E

LBA3500

Session Title: Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus

Date: Friday, May 30, 2025

Session Time: 2:45 PM – 5:45 PM

Presentation Time: 2:45 PM – 2:57 PM

Location: Arie Crown Theater

Advancing the Future of Cancer Care

At Merck, we strive every day to improve the futures of people living with cancer. Building on our 350-year global heritage as pharma pioneers, we are focusing our most promising science to target cancer’s deepest vulnerabilities, pursuing differentiated molecules to strike cancer at its core. By developing new therapies that can help advance cancer care, we are determined to create a world where more cancer patients will become cancer survivors. Learn more at www.merckgroup.com.

About Pimicotinib (ABSK021)

Pimicotinib (ABSK021), which is being developed by Abbisko Therapeutics, is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R. Pimicotinib has been granted breakthrough therapy designation (BTD) for the treatment of inoperable TGCT by China National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA), and priority medicine (PRIME) designation from the European Medicines Agency (EMA). Merck holds worldwide commercialization rights for pimicotinib.

About precemtabart tocentecan (M9140)

Precemtabart tocentecan (previously known as M9140) is an investigational anti-CEACAM5 antibody-drug conjugate (ADC). Leveraging the company’s novel linker-payload technology, precemtabart tocentecan is the first CEACAM5 ADC with an exatecan payload, a potent topoisomerase inhibitor (TOP1i), which has been rationally designed for stability in circulation and superior cancer cell killing activity. Beyond the direct effect on the target cell, precemtabart tocentecan has been shown in preclinical research to induce tumor cell death through a bystander effect permeating the cell membrane to neighboring cells, inducing apoptosis (cell death). This bystander effect within the tumor microenvironment may enhance efficacy, particularly in tumors with heterogenous CEACAM5 expression. Precemtabart tocentecan is currently being evaluated across tumor types with CEACAM5 expression and a high unmet need, including metastatic colorectal cancer (mCRC), gastric cancer (GC), non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC).

About BAVENCIO® (avelumab)

BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, BAVENCIO has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.

BAVENCIO Approved Indications

BAVENCIO® (avelumab) is indicated in the US for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. BAVENCIO is also indicated for the treatment of patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

BAVENCIO in combination with axitinib is indicated in the US for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

In the US, BAVENCIO is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).

BAVENCIO is currently approved for at least one indication for patients in more than 50 countries.

BAVENCIO Safety Profile from the EU Summary of Product Characteristics (SmPC)

The special warnings and precautions for use for BAVENCIO monotherapy include infusion-related reactions, as well as immune-related adverse reactions that include pneumonitis and hepatitis (including fatal cases), colitis, pancreatitis (including fatal cases), myocarditis (including fatal cases), endocrinopathies, nephritis and renal dysfunction, and other immune-related adverse reactions. The special warnings and precautions for use for BAVENCIO in combination with axitinib include hepatotoxicity.

The SmPC list of the most common adverse reactions with BAVENCIO monotherapy in patients with solid tumors includes fatigue, nausea, diarrhea, decreased appetite, constipation, infusion-related reactions, weight decreased and vomiting. The list of most common adverse reactions with BAVENCIO in combination with axitinib includes diarrhea, hypertension, fatigue, nausea, dysphonia, decreased appetite, hypothyroidism, cough, headache, dyspnea, and arthralgia.

About ERBITUX® (cetuximab)

ERBITUX® is an IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of ERBITUX® is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth. Based on in vitro evidence, ERBITUX® also targets cytotoxic immune effector cells towards EGFR-expressing tumor cells (antibody-dependent cell-mediated cytotoxicity [ADCC]).

ERBITUX® has already obtained market authorization in over 100 countries worldwide for the treatment of RAS wild-type metastatic colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck. Merck licensed the right to market ERBITUX®, a registered trademark of ImClone LLC, outside the U.S. and Canada from ImClone LLC, a wholly owned subsidiary of Eli Lilly and Company, in 1998.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck, generated sales of € 21.2 billion in 65 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

All Merck, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to www.Merckgroup.com/subscribe to register for your online, change your selection or discontinue this service.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250522932899/en/

 

Permalink
https://www.aetoswire.com/en/news/2305202546895

 

Contacts

Media Relations
noelle.piscitelli@emdserono.com
Phone: +1 781 427-4351

Investor Relations
investor.relations@merckgroup.com
Phone: +49 6151 72-3321

Diligent Acquires Vault, Ushering in a New Era of AI-powered Ethics and Compliance

 Acquisition Brings Vault’s Best in AI-driven Automation, Ethical Risk Intelligence, and Secure Speak Up Solution to Diligent Customers


NEW YORK & LONDON--(BUSINESS WIRE)--Diligent, the AI leader in governance, risk and compliance (GRC) SaaS solutions, today announced its acquisition of Vault, an AI-powered ethics and compliance solution that empowers organizations to foster a speak-up culture, mitigate misconduct risks, and strengthen compliance. Recognizing the limitations of outdated ethics and compliance systems, this acquisition signifies a move toward a new era of proactive integrity. By integrating Vault’s cutting-edge Speak Up technology into Diligent’s GRC platform, organizations can detect risks earlier, respond faster, and build greater trust among employees and stakeholders.


Vault’s AI-first technology expands Diligent’s ability to serve global enterprises with localized compliance features, multilingual reporting channels, and assistance with adhering to global regulations. By setting the standard for seamless, intuitive, and effective compliance tools, Vault empowers employees to report concerns safely while providing organizations with the investigation suite and insights needed to drive meaningful change.


“We’re thrilled to welcome the Vault team and clients to Diligent. This acquisition reinforces our deep commitment to leveraging cutting-edge AI technology to enhance transparency, integrity and ethical practices in global companies,” said Amanda Carty, General Manager, Compliance, of Diligent. “Now, we can ensure organizations are equipped with the proper tools to proactively comply with evolving laws like the EU Whistleblowing Directive and other regulatory frameworks worldwide, further reducing their risk exposure while building a stronger culture of integrity.”


This acquisition marks the beginning of a new chapter in ethics and compliance technology, strengthening employee trust and engagement by ensuring safe, confidential, and user-friendly reporting channels like mobile apps, web platforms, and AI-powered hotlines. Organizations now have a 360-degree compliance and ethics solution through end-to-end visibility into misconduct trends, making compliance programs more effective and defensible.


“We’re incredibly excited to join Diligent. Vault has always been pushing the boundaries in ethics technology. Now, with Diligent, our innovative platform can reach a wider audience and truly change how organizations build ethical cultures and mitigate major risks,” said Neta Meidav, Founder and CEO of Vault. “Our new combined offering will be unmatched in the market, and we look forward to transforming how ethics is handled across organizations.”


This announcement comes on the heels of Diligent’s acquisition of Spark Compliance, a leading global company specializing in ethics and compliance program design, earlier this year. This strategic acquisition of Vault underscores Diligent’s commitment to leveraging AI technology to arm GRC professionals with best-in-class solutions to truly clarify risk and elevate governance.


District Capital Partners served as the financial advisor, and Willkie Farr & Gallagher LLP served as the legal advisor to Diligent. Raz. Dlugin & Co. served as the legal advisor to Vault.


Diligent will host a webinar, The Future of Corporate Integrity: Diligent + Vault Redefine Ethics & Compliance, on Tuesday, June 3rd. Register here.


To learn more about Diligent’s acquisition of Vault, visit https://www.diligent.com/vault.


About Diligent

Diligent is the AI leader in governance, risk and compliance (GRC) SaaS solutions, helping more than 1 million users and 700,000 board members to clarify risk and elevate governance. The Diligent One Platform gives practitioners, the C-Suite and the board a consolidated view of their entire GRC practice so they can more effectively manage risk, build greater resilience and make better decisions, faster. Learn more at diligent.com.


Follow Diligent on LinkedIn and Facebook.


About Vault

Vault is the Active Integrity leader, modernizing Speak Up programs with a digital, AI-enabled platform for Speak Up, investigations, and data reporting. As the operating system for corporate integrity, Vault acts as a control center for managing misconduct reporting, investigations, and built-in analytics, all from one central solution that builds a Speak Up culture across the business. Vault is an award-winning tech startup which attracted investment from leading VCs such as Gradient, Google’s early-stage AI fund, and Illuminate Financial.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250522289404/en/



Permalink

https://www.aetoswire.com/en/news/2205202546883


Contacts

Contacts

Media Contact

Michele Steinmetz

Senior Director of Communications, Diligent

+1-215-817-5610

msteinmetz@diligent.com


 

ZincFive Expands Global Reach with Strategic EMEA Warehouse and Service Hub


 PORTLAND, Ore. 

New certified customs facility enhances European logistics, strengthens global serviceability, and advances sustainability goals

(BUSINESS WIRE)--ZincFive®, the world leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today announced a major milestone in its global growth strategy with the establishment of a new warehouse and service depot in Europe. The facility, operated in collaboration with Akkuteam Energietechnik GmbH, will support fast, efficient delivery of ZincFive batteries and spare parts across the EMEA region and beyond.


This certified customs warehouse enables seamless transit of batteries and components through Europe, streamlining exports to non-EU countries such as those in the Middle East. It also advances ZincFive’s sustainability goals by reducing shipping-related emissions and improving logistics efficiency.


The move comes in response to accelerating international demand for ZincFive’s nickel-zinc technology. With many European installations still relying on legacy lead-acid systems, there is a growing appetite for safer, more sustainable, and high-performance alternatives – making ZincFive’s technology uniquely suited to meet modern backup power needs.


“This is more than a logistical move – it’s a signal of our long-term commitment to the EMEA market,” said ZincFive CEO Tim Hysell. “Our values of innovation, sustainability, and reliability are mirrored in this new partnership. With a facility designed for efficient, environmentally responsible battery logistics, we’re not just expanding our footprint – we’re doing it the right way. We’re investing where demand is real and growing – this isn’t speculative; it’s a response to the strong pull we’re seeing from European and Middle Eastern markets.”


Akkuteam brings deep expertise in battery storage and handling and operates with a strong focus on quality and environmental stewardship. As a family-run company with a 25-year history of innovation in backup power solutions, Akkuteam’s commitment to service and future-ready infrastructure closely aligns with ZincFive’s mission to power a greener future through The Power of Good Chemistry®.


ZincFive is uniquely positioned for global growth as power demands rise across sectors – especially in data centers, including the fast-emerging AI segment. Its patented nickel-zinc chemistry – proven in the field for over a decade – delivers safe, sustainable, and high-performance energy storage that challenges the dominance of lead-acid and lithium-ion batteries. The ZincFive BC Series UPS Battery Cabinets – including the latest BC 2–500 and BC 2–300X models – offer an industry-leading footprint while delivering greater power to meet the escalating demands of modern infrastructure. Powered by the new Z5 13-90 ultra-high-rate battery, these solutions continue to raise the bar for compact design, reliability, and sustainability in mission-critical environments.


ZincFive has earned global recognition, including TIME’s 2025 World’s and America’s Top GreenTech Companies lists, the 2024 Edison Award™, CleanTech Breakthrough’s 2024 Overall Innovation of the Year, a finalist spot in the 2023 S&P Platts Global Energy Awards, and several other notable industry honors.


About ZincFive, Inc.


ZincFive is the world leader in innovation and delivery of nickel-zinc batteries and immediate power solutions. Supported by an impressive portfolio of international patents, ZincFive technology harnesses The Power of Good Chemistry® to propel the world forward. ZincFive technology leverages the safety and sustainability of nickel-zinc chemistry to provide unparalleled high power density and performance for mission critical applications. ZincFive is a privately held company based in Tualatin, Oregon. For more information, visit www.zincfive.com.


ZincFive and The Power of Good Chemistry are registered trademarks of ZincFive, Inc. and the ZincFive logo is a trademark of ZincFive, Inc.


Follow ZincFive: LinkedIn | YouTube


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250522279972/en/



Permalink

https://www.aetoswire.com/en/news/2205202546884


Contacts

Media Contact:

Ilissa Miller

iMiller Public Relations for ZincFive

Tel: +1.914.315.6424

Email: zincfive@imillerpr.com

Manhattan Associates Unveils Agentic AI Innovation at Momentum 2025


 LONDON -


(BUSINESS WIRE)--Kicking off Momentum 2025, Manhattan Associates Inc. (NASDAQ: MANH) today announced sweeping Agentic AI support within Manhattan Active® solutions that includes intelligent, autonomous digital agents to revolutionise supply chain commerce execution, optimisation, and user experiences.


These out-of-the-box AI agents, powered by large language models (LLMs) and Manhattan’s cloud-native, all-microservice API architecture, will autonomously perform tasks, adapt to changing conditions, and dynamically orchestrate workflows. This breakthrough marks a generational leap from traditional chatbots and static workflow configurations to dynamic, intelligent, and situationally aware orchestration across the entire supply chain and commerce lifecycle.


Among the first groundbreaking AI agents announced are the Intelligent Store Manager, Labor Optimizer Agent, Wave Inventory Research Agent, Contextual Data Assistant, and Virtual Configuration Consultant. These digital agents allow users to interact with Manhattan applications using natural language, understand complex requests, bypass traditional interfaces to surface data, drive optimisation, and efficiently resolve disruptions in real time across critical supply chain commerce operations.


To further empower customers and partners to innovate at their own pace, the company also launched Manhattan Agent Foundry™, a groundbreaking platform designed to enable organisations to rapidly build and deploy their own agents within the Manhattan ecosystem. Customers can now create specialised agents tailored to their unique processes and preferences, drastically reducing time-to-value, increasing automation scalability, enhancing productivity, and delivering tangible business value. They can also lean on Manhattan or third-party partners to develop these specialised agents.


“Agentic AI isn’t just another feature; it’s a transformative innovation capability tailored to redefine the future of supply chain commerce,” said Sanjeev Siotia, CTO at Manhattan. “By opening up Agent Foundry to our customers and partners, we’re ensuring that AI agent creation will not be constrained by vendor development cycles. This is part of Manhattan’s ongoing commitment to path-breaking technology that heightens efficiency and resiliency. Our best-in-class customer base now has the power to create thousands of digital agents, limited only by their imagination.”


All agents built in Manhattan Agent Foundry are compatible with emerging industry standards, including A2A and MCP protocols, ensuring seamless interoperability with third-party agent platforms such as Google Agentspace. This reinforces Manhattan’s desire to make Agentic AI a key enabler of an interconnected, AI-driven enterprise ecosystem.


Agentic AI assistants and Agent Foundry will be generally available starting Fall 2025.


Receive up-to-date product, customer and partner news directly from Manhattan on LinkedIn.


ABOUT MANHATTAN ASSOCIATES:


Manhattan Associates is a global technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers.


Manhattan Associates designs, builds and delivers leading edge cloud solutions so that across the store, through your network or from your fulfilment centre, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit https://www.manh.com/en-gb.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250522192256/en/



Permalink

https://www.aetoswire.com/en/news/2205202546867


Contacts

Press Contact:

Devika Goel

Manhattan Associates

Tel: +1 470-435-1566

dgoel@manh.com

Ant International Launches Tokenised Deposit Solutions for Real-Time Treasury Management with HSBC

 


HONG KONG - 

The company's Embedded Finance unit is expanding banking partnerships on tokenisation and AI-driven global liquidity management tools to maximize payment and treasury efficiency


(BUSINESS WIRE) -- Ant International today announced its collaboration with HSBC on the bank’s new Tokenised Deposit Service in Hong Kong. The service will support treasury management with real-time, always-on HKD and USD payments between corporate wallets held by a corporate client at HSBC Hong Kong. The Tokenised Deposit Service is also the first bank-led, blockchain-based settlement service in Hong Kong. The launch comes after a successful pilot test between HSBC and Ant International on Ant’s Whale platform, which has been rolling out blockchain-based payments and tokenised deposits solutions with various bank partners.


Following the pilot test, HSBC adapted the learnings from the joint innovation into its Tokenised Deposit Service, with Ant International as the pioneer client. As the first client to utilise the Tokenised Deposit Service, Ant International has successfully completed an instant intra-group fund transfer via the service. It initiated the transaction via its internal global treasury management platform, the Whale platform, digitising its USD deposits with HSBC into digital tokens on the bank’s secure distributed ledger.


One of the core products developed by the Platform Tech team under Ant International’s Embedded Finance business, the Whale platform is a next-generation treasury management solution that utilises blockchain technology, including advanced encryption and AI, to improve the efficiency and transparency of funds transfer between Ant International’s intragroup entities for real-time global treasury management. In 2024, more than a third of Ant International’s transactions were processed on-chain via the Whale platform.


The Whale platform currently supports multiple tokenised assets from leading banks and institutions around the world, enabling interoperability across diverse blockchain networks. By leveraging leading DLT technologies such as homomorphic encryption and zero-knowledge proofs, the Whale platform encrypts transaction information and enables multi-party verification in an encrypted state, ensuring secure, confidential, and seamless cross-chain transactions.


Ant International’s collaboration with HSBC on tokenised deposits expands a longstanding partnership since 2020. In October 2024, Ant International and HSBC also completed a successful HKD-denominated cross-bank experiment under the Hong Kong Monetary Authority’s Ensemble Sandbox.


“We are very excited to work with an industry leader like HSBC, who shares the belief that tokenisation is the key to bridging the stability of traditional banking with the efficiency of blockchain, to enable real-time treasury management," said Kelvin Li, General Manager of Platform Tech at Ant International. "As a tech connector in the fast-evolving financial services industry, our banking partnerships are expanding from tokenisation to AI-driven global FX and liquidity initiatives. We look forward to working with more public and private-sector partners to unlock more transparent, accessible and efficient treasury management solutions for businesses worldwide.”


About Ant International


With headquarters in Singapore and main operations across Asia, Europe, the Middle East and Latin America, Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250522743088/en/



Permalink

https://www.aetoswire.com/en/news/2205202546888


Contacts

Media Contacts

Ant International

Kahmun Leong

Kahmun.leong@ant-intl.com